Search

Displaying results 2491 - 2500 of 10000 in total
  1. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    Tisotumab vedotin is a tissue factor-directed antibody-drug conjugate (ADC) comprised of an anti-tissue factor (TF) human IgG1-kappa antibody conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting … TF is a novel target for cancers, as it is often overexpressed on solid tumours, including cervical cancer, and it is associated with poor clinical outcomes.

  2. Drug

    Testosterone cypionate

    go.drugbank.com/drugs/DB13943
    ApprovedInvestigational

    It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979. … Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester.

    Products: DEPO-TESTOSTERONE STERILE SOLUTION 100 mg/ml, DEPO-TESTOSTERONE STERILE SOLUTION 200 mg/ml
  3. Drug

    Oxilofrine

    go.drugbank.com/drugs/DB11610
    Approved

    Oxilofrine is used in combination with [DB11609] as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.

  4. Drug

    Quinidine barbiturate

    go.drugbank.com/drugs/DB01346
    Approved

    A papulopurpuric eruption in a patient (without thrombopenia) can be developed who is taking quinidine phenylethyl barbiturate intermittently and at reintroduction.(PMID: 9739909)

    Products: NATISEDINE 100 MG TABLET, 20 ADET
  5. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis. … [A253642,A253647] It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and [elagolix].

  6. Drug

    Tropisetron

    go.drugbank.com/drugs/DB11699
    ApprovedInvestigationalWithdrawn

    As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting … Tropisetron is an indole derivative with antiemetic activity.

    Products: NAVOBAN 5MG, NAVOBAN 5 MG 1 AMPUL
  7. Drug

    Oprelvekin

    go.drugbank.com/drugs/DB00038
    ApprovedInvestigationalWithdrawn

    Oprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology. … However, it displays comparable biological activity compared to the natural IL-11 _in vitro_ and _in vivo_. Oprelvekin works by stimulating megakaryocytopoiesis and thrombopoiesis.

  8. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    It functions by blocking the enzyme orotate phosphoribosyltransferase (OPRT), which is involved in the production of 5-FU. … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells.

  9. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335] and in the US in March 2024.[L50291,L50296] … [A249920] It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since become one of the most popular cosmetic procedures worldwide.

  10. Drug

    Naxitamab

    go.drugbank.com/drugs/DB15965
    ApprovedInvestigational

    [L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely … Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.